623144-24-1 Usage
Type of Compound
Chemical derivative of quinoline
Dichlorophenyl group
A chlorine-based group that contributes to the compound's chemical structure and properties.
Antiviral properties
DCPIQ has been shown to inhibit the replication of certain viruses, such as herpes simplex virus (HSV).
Antimicrobial properties
The compound exhibits the ability to kill or inhibit the growth of microorganisms, making it a potential candidate for new antibiotics.
Treatment of herpes simplex virus (HSV) infections
DCPIQ's antiviral properties make it a promising option for treating HSV infections.
Development of new antibiotics
The antimicrobial properties of DCPIQ could lead to the creation of new antibiotics to combat bacterial infections.
Ongoing Research
Studies are being conducted to explore the potential of DCPIQ in treating infectious diseases and its broader applications in the field of medicine.
Check Digit Verification of cas no
The CAS Registry Mumber 623144-24-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,2,3,1,4 and 4 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 623144-24:
(8*6)+(7*2)+(6*3)+(5*1)+(4*4)+(3*4)+(2*2)+(1*4)=121
121 % 10 = 1
So 623144-24-1 is a valid CAS Registry Number.
623144-24-1Relevant academic research and scientific papers
2,6-Quinolinyl derivatives as potent VLA-4 antagonists
Lassoie, Marie-Agnes,Broeders, Fabienne,Collart, Philippe,Defrere, Laurent,de Laveleye-Defais, Francoise,Demaude, Thierry,Gassama, Abdoulaye,Guillaumet, Gerald,Hayez, Jean-Claude,Kiss, Laszlo,Knerr, Laurent,Nicolas, Jean-Marie,Norsikian, Stephanie,Quere, Luc,Routier, Sylvain,Verbois, Valerie,Provins, Laurent
, p. 142 - 146 (2007/10/03)
A new series of 2,6-quinolinyl derivatives was prepared leading to potent low nanomolar VLA-4/VCAM-1 antagonists.
2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS
-
Page/Page column 58, (2010/02/07)
The present invention concerns 2,6-quinolinyl and 2,6-naphthyl derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for the treatment of VLA-4 dependent inflammatory diseases such as for example asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and atherosclerosis. Formula (I): wherein X is N or CH.
